Get started
Author

Destiny J. West

Observed name: Destiny West
ORCID: 0009-0004-5960-5271
Observed ORCID: 0009-0004-5960-5271
OpenAlex ID: A5081239309
Integrative clinical and molecular characterization of translocation renal cell carcinoma
2022 · Ziad Bakouny, Ananthan Sadagopan, et al. · Cell Reports · 124
PDF
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
2025 · Miya B. Hugaboom, Lena V. Wirth, et al. · Cancer Discovery · 50
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
2023 · Thomas Denize, Opeyemi A. Jegede, et al. · Clinical Cancer Research · 36
PDF
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway
2022 · Laura A. Stransky, Sean M. Vigeant, et al. · Proceedings of the National Academy of Sciences · 35
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
2022 · Thomas Denize, Yue Hou, et al. · Clinical Cancer Research · 26
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy
2024 · David J. Einstein, Brian Halbert, et al. · Journal of Immunotherapy · 7
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.
2023 · Nourhan El Ahmar, Sayed Matar, et al. · Journal of Clinical Oncology · 4
PDF
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al. · Clinical Cancer Research · 2
PDF
38Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
2025 · Lena Wirth, Miya Hugaboom, et al. · The Oncologist · 1
PDF
Data from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
2025 · Miya B. Hugaboom, Lena V. Wirth, et al. · 1
Supplementary Data from Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
2023 · Thomas Denize, Yue Hou, et al. · 1
Supplementary Figure from Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
2023 · Thomas Denize, Yue Hou, et al. · 1
Supplementary Table S9 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S6 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S4 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S7 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S11 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S10 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S1 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Data from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S8 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Works count: 123
Citation count: 288
H-index: 6
I10-index: 5
Year
Topic
Type